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Abstract
Purpose Patient blood management [PBM] has been acknowledged and successfully introduced in a wide range of medical 
specialities, where blood transfusions are an important issue, including anaesthesiology, orthopaedic surgery, cardiac sur-
gery, or traumatology. Although pregnancy and obstetrics have been recognized as a major field of potential haemorrhage 
and necessity of blood transfusions, there is still little awareness among obstetricians regarding the importance of PBM in 
this area. This review, therefore, summarizes the importance of PBM in obstetrics and the current evidence on this topic.
Method We review the current literature and summarize the current evidence of PBM in pregnant women and postpartum 
with a focus on postpartum haemorrhage (PPH) using PubMed as literature source. The literature was reviewed and analysed 
and conclusions were made by the Swiss PBM in obstetrics working group of experts in a consensus meeting.
Results PBM comprises a series of measures to maintain an adequate haemoglobin level, improve haemostasis and reduce 
bleeding, aiming to improve patient outcomes. Despite the fact that the WHO has recommended PBM early 2010, the 
majority of hospitals are in need of guidelines to apply PBM in daily practice. PBM demonstrated a reduction in morbidity, 
mortality, and costs for patients undergoing surgery or medical interventions with a high bleeding potential. All pregnant 
women have a significant risk for PPH. Risk factors do exist; however, 60% of women who experience PPH do not have a 
pre-existing risk factor. Patient blood management in obstetrics must, therefore, not only be focused on women with identi-
fied risk factor for PPH, but on all pregnant women. Due to the risk of PPH, which is inherent to every pregnancy, PBM is of 
particular importance in obstetrics. Although so far, there is no clear guideline how to implement PBM in obstetrics, there 
are some simple, effective measures to reduce anaemia and the necessity of transfusions in women giving birth and thereby 
improving clinical outcome and avoiding complications.
Conclusion PBM in obstetrics is based on three main pillars: diagnostic and/or therapeutic interventions during pregnancy, 
during delivery and in the postpartum phase. These three main pillars should be kept in mind by all professionals taking care 
of pregnant women, including obstetricians, general practitioners, midwifes, and anaesthesiologists, to improve pregnancy 
outcome and optimize resources.
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Introduction
Patient blood management (PBM) has recently been intro-
duced in several areas in medicine. It comprises a series 
of measures and methods to maintain an optimal haemo-
globin (Hb) level, optimise haemostasis, minimise blood 
loss, and limit blood transfusions aiming to improve 
patient outcomes. Recent studies have shown that the 
use of PBM minimizes perioperative bleeding, reduces 
the requirement of blood transfusion [1–8], periopera-
tive morbidity [1–4], mortality, duration of hospitaliza-
tion [1, 4], and costs [9, 10]. Regarding this, the World 
Health Organization (WHO) was recommending since 
2010 to urgently implement PBM [11]. Some hospitals 
have already successfully implemented PBM notably 
in Australia [7], Europe [2, 4–6], United States [3], and 
also in Asia. However, many obstetricians and obstetrical 
departments still are in need of guidance for the imple-
mentation of PBM in daily clinical practice. Despite the 
demonstrated benefits, challenges and mindsets limit the 
implementation of PBM guidelines into daily medical 
practice [12]. These challenges can be due to ignorance, 
lack of cross-functional engagement, limited resources, 
and miss conception of PBM benefits, which may even 
create a fear of job loss in blood donor service or transfu-
sion medicine.
Introducing PBM in a hospital requires that the 
involved physicians and health care providers give up the 
sometimes-dogmatic idea that blood transfusions are the 
first line treatment to correct low haemoglobin values. 
PBM is based on three pillars (Table 1): (1) anticipa-
tion, detection, and correction of preoperative/prepartum 
anaemia; (2) prevention and reduction of perioperative/
peripartum red blood cell (RBC) loss; and (3) optimizing 
postoperative/postpartum treatment of anaemia, including 
the restrictive use of red blood cell transfusions. Probably, 
the most difficult task is to convince hospital leaders of 
the importance of PBM and to change the culture of medi-
cal management among colleagues.
Method
With this literature review, we aimed to identify: (a) the 
patient at risk of PPH; (b) the need of PBM in obstetrics; and 
(c) PBM programs implementation in the field of obstetrics. 
The rationale for this literature review was to identify gaps in 
knowledge and to provide recommendations for the improve-
ment of antenatal care for health care professionals in this 
crucial and fast evolving field of patient blood management.
Databases searched included PubMed, Scopus, CINAHL, 
Google, WHO guidelines database, Cochrane Library, and 
Web of Science, using search terms: PBM, PBM in obstet-
rics, blood transfusion, volume management, anaemia in 
pregnancy, and PPH. In total, 1250 articles were screened. 
Among them, 410 were relevant for this review.
Results and discussion
Challenges of PBM in obstetrics
Due to the risk of postpartum haemorrhage (PPH), which 
is inherent to every pregnancy, PBM is of particular impor-
tance for obstetrics. Implementation of PBM in obstetrics 
provides the opportunity to minimise bleeding and blood 
transfusions. However, large well-designed clinical studies 
are missing in this field.
It is more challenging to implement PBM in obstetrics 
than in other specialties. Furthermore, personnel, commodi-
ties, infrastructure, and a universal access to comprehensive 
obstetric care for the pregnant women are prerequisites [13]. 
In obstetrics, there are several guidelines for the manage-
ment of PPH. Most management recommendations are simi-
lar; only minor differences exist due to the lack of published 
solid clinical outcomes. Comparing guidelines for PPH in 
different obstetrical societies and international groups, there 
are important differences regarding RBC transfusions and 
PBM [14].
Challenges of PBM include identification of women at 
high risk (patient in whom PPH is likely to occur and where 
Table 1  PBM in obstetrics requires medical and surgical/interventional strategies for prevention and treatment of PPH
Medical strategies Surgical/interventional strategies
Pre-partum
 Correction of anaemia
Intra-partum
 Uterotonics [PPH prevention and treatment]
 Active coagulation management in PPH (Tranexamic acid, Fibrinogen, FFP)
Post-partum
 Correction of anaemia
 Avoid unnecessary blood transfusions
Surgical technique minimizing blood loss (prevention of PPH)
Balloon catheter
Compression sutures
Embolisation
Cell salvage and autologous transfusion
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RBC transfusion constitutes the standard of care), imple-
mentation of medical and surgical/interventional strategies, 
and restrictive but clinical appropriate blood transfusion in 
patients who need it. A multidisciplinary approach is prereq-
uisite for the success of PBM in obstetrics, including mid-
wives, obstetricians, anaesthetists, interventional radiolo-
gists, and haematologists. Albeit PBM is better described in 
planned surgery like an elective caesarean section, it should 
 be applied to any procedure with a certain likelihood of 
excessive bleeding, including vaginal delivery or non-elec-
tive caesarean section. PBM in obstetrics starts during ante-
natal care or even preconceptionally.
Haemodynamic changes during pregnancy
In pregnancy, a range of physiological modifications in the 
haemodynamic, cardiovascular, and coagulation-fibrinolysis 
systems occur that are designed by nature to prevent blood 
loss during delivery. During the first trimester, there is an 
increase in blood volume [15]. The volume of blood con-
tinues to expand rapidly during the 2nd trimester (30–50%) 
before it reaches a stable level in the last 3 months. In par-
allel, the amount of RBC increases but to a lesser extent 
(20%), leading to a relative anaemia due to haemodilution 
[16], which reaches its maximum by 30–32 weeks of preg-
nancy. Dilutional decrease of haemoglobin is, therefore, 
a common physiological process in pregnancy, especially 
between weeks 28 and 34, when haemoglobin concentra-
tions are lowest. In the first months of pregnancy, the red 
blood cell mass increases about 18–25%, followed by a 
drop after childbirth due to peripartal haemorrhage [17–19]. 
The increase in RBC mass ensures enough oxygen for the 
increased demands from both mother and foetus. These 
physiological changes have considerable advantages dur-
ing pregnancy: The placenta has a better perfusion, the risk 
of thrombosis decreases, and an adequate blood supply is 
ensured despite the bleeding that occurs with childbirth 
[20–22]. Uterine artery blood flow increases during preg-
nancy (10 times) and reaches 450-750 ml/min at term [23].
In parallel, there is a substantial increase in clotting 
capacity with an increase of the coagulation factors I (fibrin-
ogen), VII, VIII, IX, X, XII and von Willebrand factor. Fur-
thermore, there is a decrease of F XIII and a physiologic 
decrease of protein S, while F II, V and protein S do not 
change [24].
The elevation of plasminogen activator inhibitors 1 and 
2 diminishes fibrinolytic activity. Thus, there is an increase 
of the thromboembolic risk. In summary, haemodynamic 
and haemostatic changes represent adaptations of nature to 
the challenges of reproduction and are prerequisites for a 
successful pregnancy outcome of the mother and her child. 
Nevertheless, PPH remains a main factor of maternal mor-
bidity and death during childbirth [25].
Causes of postpartum haemorrhage
Main reasons for severe PPH include uterine atony, retained 
placenta, placenta praevia, placenta accreta, placental abrup-
tion, trauma involving uterine rupture, or lower genital tract 
trauma and primary coagulopathy [26–28]. The causes of 
PPH from a clinical perspective are best summarized as the 
4 T’s: Trauma (of birth canal), Tissue (remaining placenta 
or placental pieces), Tone (decreased uterine muscular 
tone: atony), and Thrombin (coagulopathy). Women with 
previous PPH in the last pregnancy, pre-existing anaemia, 
prior caesarean section, multiple gestation, uterine fibroma, 
preeclampsia, obese women, chorioamnionitis, and foetal 
macrosomia are at increased risk for PPH [29].
However, PPH can occur in every pregnant woman, 
and most women (61%) with PPH do not have a risk factor 
excluding maternal age and caesarean section [30]. There-
fore, we have to consider that all pregnant women are at a 
considerable risk for PPH. As a consequence, it is also not 
possible to define those women who have a very low risk 
for PPH.
Iron deficiency and anaemia in pregnancy
Preoperative anaemia is often neglected in surgery. The 
surgical intervention is often performed as planned, and 
blood is given when considered necessary (part of the stand-
ard care) [12]. In obstetrics, there is a unique opportunity 
to detect iron deficiency and anaemia a long time before 
a potential blood loss, as well as in each of the following 
visits of pregnancy care. Therefore, optimal prerequisites 
exist to implement the first pillar of PBM, and they essen-
tially include the optimization of the red blood cell mass at 
delivery. In general, anaemia occurs frequently in pregnant 
women and is mostly associated with iron deficiency. Other 
causes include haemoglobinopathies [thalassemia, sickle 
cell anaemia], infections [hook worm, malaria], Vitamin  B12 
deficiency, or chronic inflammation. In 2011, the percentage 
of anaemic pregnant women worldwide was 38%, with wide 
range between different regions: For example, in the Middle 
East Region, 48.7% of the pregnant women had anaemia, in 
Africa 46.3%, and in Europe 25.8% [31]. In most cases, it 
is in theory possible to find the reason for anaemia and to 
treat it correctly during pregnancy, thereby improving the 
outcome of mother and child.
Due to the lack of clear data reference, haemoglobin val-
ues (Hb) during pregnancy are discussed controversially. 
According to the WHO, during pregnancy, the diagnosis of 
anaemia is confirmed if Hb is < 11 g/dL [32]. It is of use to 
have different Hb reference values in each pregnancy trimes-
ter, because it is recognized that between 3 and 6 months of 
pregnancy Hb-value is reduced by 0.5 g/dL.
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The primary reason for anaemia in pregnancy is iron 
deficiency [31]. Iron need increases considerably during 
pregnancy. Most of the time, iron stores are insufficient to 
fulfil this increase, which is the consequence of physiologi-
cal changes (erythrocytes mass ~ 450 mg, placenta ~ 80 mg, 
bleeding during vaginal delivery birth ~ 250 mg, and foe-
tus ~ 225 mg). The iron needs during pregnancy are esti-
mated to 1 g of additional iron. If the women breastfeeds her 
child, she will need an extra 1 mg iron per day [33]. Bone 
marrow biopsies showed that if no extra iron is provided 
during pregnancy, 80% of subjects will have exhausted iron 
reserves at delivery [18]. Of course, the above-mentioned 
other reasons for anaemia have to be considered and if nec-
essary treated [32–34].
NICE (The English National Institute for Health and Care 
Excellence) recommends a complete blood count at the 
beginning of pregnancy and at 28 week gestation, to allow 
an optimal treatment if anaemia is diagnosed [35]. Other 
national societies, such as the Swiss Society of Gynaecol-
ogy and Obstetrics (SSGO), recommend a full blood count 
and a ferritin value at booking, and thereafter haemoglobin 
levels every trimester. The reason for low Hb levels should 
be clarified and supplementation (iron,  B12, etc.) initiated if 
needed. If anaemia is diagnosed during pregnancy, the fol-
lowing haematological investigations can elucidate the cause 
of anaemia: a mean red cell volume (MCV) can support 
the clarification of the causes of anaemia. It can advocate: 
(a) microcytic anaemia due to iron deficiency or haemoglo-
binopathy; (b) macrocytic anaemia related to deficiency in 
vitamin  B12 or folate; and (c) normocytic anaemia related to 
maternal diseases/infections. Of note, in many cases, anae-
mia in pregnancy is a mixed form of anaemia, such as iron 
deficiency combined with vitamin  B12 deficiency, which 
may render red blood cell indices less reliable as diagnos-
tic feature. Complementary blood tests are often necessary, 
and include several haematinic parameters (ferritin, vitamin 
 B12, and folate). In particular circumstances, to exclude hae-
molysis and make a final classification of anaemia, addi-
tional haematological and/or enzymatic parameters should 
be performed [36–38]. In cases of microcytic anaemia with 
normal ferritin, investigation of haemoglobinopathies should 
be undertaken depending on the origin of the patient.
Iron deficiency can, therefore, not be excluded if the 
MCV is normal. Haemoglobinopathies should always be 
suspected in case of severe hypochromic microcytic anae-
mia. Red cell distribution width (RDW) may help to differ-
entiate iron deficiency from other microcytic anaemias, e.g., 
in case of haemoglobinopathies. Thus, if mean corpuscular 
haemoglobin is below 26 pg, it is important to screen for 
haemoglobinopathies in case of normal iron stores. Regard-
ing iron stores, serum ferritin seems to be the best and most 
practical marker. In pregnancy, a serum ferritin concentra-
tion < 30 µg/L implies insufficient or empty iron stores and, 
therefore, an increased risk for developing iron deficiency 
anaemia. A serum ferritin value < 12 µg/L implies estab-
lished iron deficiency with empty iron stores at all stages 
of pregnancy [36–38]. As an acute-phase protein, ferritin 
increases during inflammation or infectious episodes. There-
fore, the measurement of the C-reactive protein (CRP) level 
at the same time is recommended. A normal serum ferritin 
value does not exclude iron deficiency in inflammatory situ-
ations. Because iron deficiency is very common in preg-
nancy, serum ferritin screening during first trimester is in 
several most recent recommendations, for example, by the 
SSGO [40]. If iron stores are empty in early pregnancy, iron 
treatment is medically indicated even if the haemoglobin 
is still normal. As iron demand increases during gestation, 
untreated iron deficiency will result in incremental anaemia. 
As outlined above, women suffering from anaemia have an 
increased risk during PPH or even moderate bleeding.
Prevention and treatment of antepartum iron 
deficiency and anaemia
To prevent iron deficiency and iron deficiency anaemia, an 
alimental iron supplementation of 30–60 mg/day is recom-
mended by the WHO [39] for all pregnant women. There is 
no recommendation neither in the UK nor in Switzerland for 
routine iron supplementation in all pregnant women [40, 41]. 
In countries with an increased prevalence of iron deficiency 
and anaemia, particularly in low resource countries, routine 
supplementation of iron seems to be an appropriate strategy. 
However, iron supplementation may cause undesirable side 
effects such as gastric pain or constipation in up to 25% 
of pregnant women [42]. Therefore, targeted iron treatment 
in women with iron deficiency anaemia or low iron stores 
without anaemia is the preferred strategy in populations in 
which iron deficiency in pregnant women is not extremely 
high. Hence, it is recommended to check serum ferritin at 
the beginning of pregnancy and offer oral iron supplementa-
tion if serum ferritin is below 30 ng/ml.
In women with mild-to-moderate iron-deficiency anaemia 
during the first and second trimesters, it is advised to have a 
daily oral iron substitution (160–200 mg/day of iron) [40]. 
This is also applicable for iron deficiency without anaemia 
in early pregnancy (serum ferritin < 30 ng/mL) knowing that 
the iron need will increase during gestation [40, 41, 43].
Intravenous iron is recommended if there is intolerance 
to oral iron preparations (gastrointestinal side effects) if 
Hb levels do not increase appropriately (less than 1 g/dL 
within 14 days) due to impaired intestinal absorption or poor 
compliance, in cases with severe, advanced or progressive 
anaemia (Hb < 9 g/dL), or if a rapid anaemia treatment is 
necessary due to advanced gestational age or in Jehovah’s 
witnesses [32, 40]. The choice of parenteral iron preparation 
depends on the products availability in different countries. 
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Today, iron dextran products are not recommended due to 
the increased risk of anaphylactic reactions compared to the 
newer intravenous iron products available (i.e., ferric car-
boxymaltose, iron sucrose, iron gluconate, etc.) [44]. Based 
on the available clinical trial data of iv iron treatment in 
pregnancy [45–48], in Switzerland, the SSGO recommends 
ferric carboxymaltose use as best treatment choice when 
parenteral iron use is appropriate [40].
Management of the woman during delivery
Risk factors for PPH are older age, multiple gestations, 
preeclampsia, induction of labour, uterine fibroma, polyhy-
dramnios, placenta praevia, and placenta accreta spectrum 
disorder. The mode of delivery cannot be considered as a 
predictor for PPH, although caesarean section is associated 
with a higher average blood loss as compared to vaginal 
birth. Recent evidence suggests an association between 
a low pre-partum haemoglobin and an increased risk of 
PPH. In an observational study with 53 patients with PPH, 
21 women had emergency hysterectomy because of seri-
ous uterine atony, whereas the remaining 32 women were 
responsive to standard of care (conservative measures) [49]. 
Prepartum haemoglobin value was low (< 7 g/dL) in 81% of 
women with hysterectomy and PPH (n = 17/21) compared 
to 12.5% of the non-hysterectomised women. These data 
showed a strong relationship between anaemia (low Hb val-
ues < 10 g/dL) and risk of PPH. The rationale behind this 
may be decrease myometrial contractility and/or impaired 
coagulation due to low Hb levels.
Among the most current guidelines are those of the Ger-
man, Austrian, and Swiss Societies for Gynaecology and 
Obstetrics published in 2018 and the RCOG (Royal Col-
lege of Obstetricians and Gynaecologists) published in 2017 
[50, 51]. Risk factors for PPH are often present before birth, 
according to retrospective studies in about 40% of women 
with PPH. In these women, the clinical management dur-
ing gestation must be modified. One important issue is the 
facility of birth: Women with a potential of haemorrhage 
are advised to give birth in a centre, where all required care 
is onsite.
During delivery, blood loss evaluation is often challeng-
ing, but important for clinical management of the patient 
if bleeding is increased. Typically, blood loss is underesti-
mated by 50% during vaginal delivery. Blood collecting bags 
or weighing swaps may help for a more accurate estimation 
of blood loss. The rapid and appropriate management in case 
of PPH is crucial to reduce morbidity and, in particular, 
reduce the need of blood transfusions. Clinicians should be 
prepared and well trained to use timely appropriate medi-
cation, as well as mechanical and surgical interventions to 
stop PPH. The key factor is to perform a rapid but thorough 
examination to identify the cause of haemorrhage (4TS) and 
treat it accordingly. The therapy of PPH after vaginal birth 
or caesarean section depends on the clinical situation and 
the cause of PPH (4 T’s: Trauma, Tissue, Tone, Thrombin, 
see above) and consists of different therapeutic measures: 
Suturing of tissue laceration in birth canal or uterine rupture, 
surgical removal of placental tissue, uterotonic medications, 
and administration of Pro-coagulants. If bleeding persists, 
further measures include insertion of a Balloon-tamponade 
of the uterus, surgical intervention such as uterine com-
pression sutures (B-Lynch, Hayman technique, or others 
[52]) or uterine vessel mass ligation. In haemodynamically 
stable patients, emergent transfer to interventional radiol-
ogy department and uterine artery embolization may be an 
effective and often successful intervention [53]. Finally, hys-
terectomy might become necessary as ultima ratio if other 
measures were unsuccessful.
Prevention of PPH
To minimise the risk of PPH, Cochrane reviews [54–56] 
have shown that the proactive management of the third stage 
of labour which consists of prophylactic administration of 
uterotonics such as oxytocine, carbetocin, or ergometrine is 
successful in preventing PPH. The main component of the 
package is the use of oxytocin or carbetocin, as controlled 
cord traction adds only very little [57]. Early cord clamping 
limits the blood volume to the newborn and may lead to iron 
deficiency and anaemia in preterm born babies [58]. It has 
been shown that delaying umbilical cord clamping (mini-
mum 1 min.) have an extended benefit (up to infancy) for the 
new-born [59]. Therefore, systematic early clamping of the 
umbilical cord is not advised anymore, except in emergency 
cases such as severe foetal distress or placental abruption.
Fluid management
Several physiological changes occur during pregnancy. In 
the first months, the body of the pregnant woman holds 
off about 500 up to 900 mEq of sodium [60–62], which 
increases the body water volume by 6–8 L. Development 
of resistance to angiotensin II occurs in parallel to an 
upregulation of the renin-angiotensin system. This leads 
to a broad rise of 4–7 L in the volume of extracellular 
water and a reduction of sodium and water elimination 
to keep a physiologic blood pressure [63, 64]. Stroke 
volume and heart rate increase. Cardiac output rises rap-
idly at the beginning of the 5th week of gestation (first 
trimester) and continues until the 32nd week. It reaches 
the maximum around the 6th month of pregnancy, hav-
ing reached ~ 130–150% of the values of non-pregnant 
women. After birth, cardiac output decreases and turns 
back to normal levels only at 24 week postpartum. Colloid 
osmotic pressure (COP) may decrease from 25 mmHg to 
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18–20 mmHg and cause oedema. All the factors mentioned 
above should be kept in mind and taken into consideration 
for the fluid management of complicated obstetric patients.
During severe PPH, decreased cardiac output, hypoten-
sion, and vasoconstriction may cause a decrease in end-
organ perfusion of vital organs, including kidneys, heart, 
and brain [65]. Fluid management is a crucial component 
of PPH treatment to maintain adequate tissue perfusion. 
Not only blood loss is difficult to estimate, the same is true 
for volume status of the patient. Due to the physiological 
increase in blood volume and cardiac output, the parturient 
may present with cardiovascular stability despite signifi-
cant blood loss. Shock index (heart rate divided by systolic 
blood pressure) above 1 is considered a helpful marker to 
identify relevant hypovolaemia [66]. Maternal lactate is 
also used by anaesthetists to monitor tissue hypo perfusion 
in case of significant blood loss. It is important to appro-
priately warm the infused volume to avoid hypothermia, 
which has a negative impact on coagulation, oxygenation 
acidosis [67]. There is no consensus on the choice of crys-
talloid or colloidal infusion [68] and there is no standard 
for the appropriate volume of resuscitation fluids [69–71].
Treatment of PPH 
Uterine atony is the most frequent reason for PPH. 
Therefore, methods to stimulate contractions of 
the myometr ium should be used. According to 
Mavrides et  al. (a Cochrane review), the manage-
ment can start at the following sequence [50, 72]: 
1. Uterine fundus palpation and rubbing for stimulation of 
contractions.
2. Bladder emptying (leave the Foley catheter in place). 
Ensure a complete placenta or uterine vacuity if doubt.
3. Intravenous injection (i.v.) of Oxytocin 5 IU (additional 
dose might be needed).
4. Parenteral administration of Oxytocin (40 IU in 500 mL 
isotonic solution at 125 ml/h) except if there is a need of 
fluid limitation.
5. If the previous interventions did not lead to appropri-
ate response, sulprostol should be administered by con-
trolled infusion.
6. In case of non-availability of sulprostol, 800 micrograms 
of misoprostol can be used rectally or other uterotonics 
including prostaglandin F2alpha or ergometrin may be 
administered.
Expert consensus supports the use of these methods, even 
though no evidence-based trial was published [73].
Tranexamic acid
Antifibrinolytics such as aminomethylbenzoic acid, apro-
tinin, aminocaproic acid, and tranexamic acid diminish 
bleeding. They act by the inhibition of fibrin clots break-
down [74, 75]. It has been shown in surgery that tranexamic 
acid can reduce bleeding and consequently reduce by 1/3 
the need for RBC transfusion [76]. Large clinical trials have 
shown that early administration of tranexamic acid reduced 
mortality in trauma patients. Similarly, a large multicentre 
RCT in women with PPH has shown reduction of morbid-
ity as well as mortality. Importantly, the effect was best 
if tranexamic acid was administered within the three first 
hours after the onset of the haemorrhage [77–79]. It is of 
note that in these patients, most severe bleeding and death 
occurs within 12 h after haemorrhage start. In PPH, death 
peaked 2–3 h after delivery. The important WOMAN trial 
has shown that there is an improvement of survival with 
the use of tranexamic acid [78]; however, it should be used 
rapidly otherwise the benefit reduces by 10% per 15 min 
delay up to no benefit reported after 3 h [80]. Of note, the 
WOMAN trial has been subject to criticism regarding the 
issues of the included patient population and regarding the 
number needed to treat. Patients with increased blood loss 
during vaginal birth or caesarean section should receive anti-
fibrinolytic drugs as soon as possible for the reasons men-
tioned above. While bleeding, the first coagulation factor to 
drop to critically low levels is fibrinogen. Therefore, early 
inhibition of fibrinolysis is reasonable and tranexamic acid 
must be given before substitution of fibrinogen. Early admin-
istration of tranexamic acid is, meanwhile, recommended as 
the first line of treatment for women with increased blood 
loss during birth.
In women who were treated prophylactically with 
tranexamic acid (1 or 0.5 g i.v.) plus the usual uterotonics 
after vaginal delivery or caesarean section, bleeding beyond 
400 or 500 ml was less frequent [81]. A French randomised 
controlled study comparing 1 g of prophylactic tranexamic 
acid with placebo showed an effect on the incidence of PPH 
[82]; however, more data are needed before prophylactic 
tranexamic acid can be recommended [50].
Red blood cell transfusion
During PPH, it is of high importance to make the difference 
between active bleeding and non-active bleeding regard-
ing the indication for RBC transfusion. In principle, during 
active bleeding in the acute phase of PPH, the dynamic of 
the clinical situation can be extremely high, and quick RBC 
transfusions often save the life of the patient. Criteria for 
transfusion mainly include estimation of blood loss, haemo-
dynamic situation and tissue oxygenation level (lactate), hae-
moglobin (Hb)/haematocrit (Ht), and prediction of severity 
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of PPH (e.g., by measuring fibrinogen). Measuring just Hb/
Ht is not the most reliable way to monitor the progress of 
the clinical situation. Assessment can be inaccurate leading 
to a delay of blood transfusion; therefore, further clinical 
criteria need to be taken into account for an optimal moni-
toring of the situation, specifically haemodynamic criteria. 
In haemorrhage and resuscitation, the European Society 
of Anaesthesiology advocates that Hb/Ht along with base 
deficit and serum lactate should be measured repeatedly for 
tissue perfusion and oxygenation evaluation [83]. It should, 
however, be kept in mind that physiological metabolic com-
pensation of respiratory alkalosis is common in pregnancy, 
and therefore, a base deficit of up to -3 is physiological. Base 
deficit with a concomitant increase of serum lactate is a sign 
of hypoperfusion, usually due to hypovolemia. Correction of 
hypovolemia with crystalloid fluids might unmask anaemia.
In the later phase of PPH, when bleeding is stopped, 
active (internal) blood loss is excluded and the haemody-
namic stability and compensation of the patient is con-
firmed, the indication for blood transfusion should be more 
restrictive with no fixed criteria for RBC transfusions [84, 
85]. Hb below 6 g/dL does usually require a RBC transfu-
sion, while this is rarely the case in a haemodynamically 
stable situation with an Hb of 8 g/dL or above. Between 6 
and 8 g/dL, transfusion indication should be more restrictive, 
depending on the clinical situation and on patient’s symp-
toms. Often, red blood cell transfusion can be avoided, and 
instead, intravenous iron treatment can be initiated 8if iron 
stores have been short) for rapid recovery of Hb levels and 
alleviation of clinical symptoms.
Fibrinogen concentrate
Fibrinogen is an acute phase protein and is essential for 
effective haemostasis. It has been shown that fibrinogen 
levels measured during PPH correspond well to the sever-
ity of PPH, although it is unclear if low fibrinogen values 
contribute to the pathogenesis of PPH or are a secondary 
phenomenon of blood loss [86–88]. Several studies [89–96] 
have suggested that fibrinogen might be useful in normaliz-
ing standard laboratory tests in PPH associated with hypofi-
brinogenaemia. Much of the evidence supporting a benefit 
of fibrinogen concentrate for PPH is based on case series, 
retrospective register investigations, or uncontrolled, non-
randomised studies [97]. Despite this, early administration 
of fibrinogen has already been included in most guidelines 
[98]. For example, the European Society of Anaesthesiology 
recommends to provide fibrinogen if the levels are < 2 g/
dL [83], this is also the case for several obstetric societies 
like the RCOG [50]. Fibrinogen concentrate is associated 
with reduced bleeding and a decreased need for transfu-
sions in PPH. Fibrinogen concentrate should be given in 
severe PPH, particularly if fibrinogen levels are low. Because 
measurement of fibrinogen levels is time consuming and, 
therefore, impractical in ongoing PPH, bedside tests, such 
as thromboelastometry, are recommended. This may enable 
a rapid correction of coagulopathy due to consumption and 
dilution [99].
Transfusion of fresh frozen plasma
Fresh-frozen plasma (FFP) has a limited clotting capac-
ity and is inferior to fibringogen concentrate for the treat-
ment of hypofibrinogenaemia. As a colloidal infusion, FFP 
is given for volume resuscitation in situations with severe 
hypovolemia and concomitant coagulopathy. Thawing FFP 
is time-consuming, and therefore, timely organisation of FFP 
is recommended [50].
Recombinant activated human factor VII (rhFVIIa)
Recombinant human factor VIIa (rhFVIIa) is a tissue fac-
tor-activated prohaemostatic agent. Even in severe PPH, the 
systematic use of rhFVVa has not been recommended [49]. 
Efficacy of rhVIIa has been shown in non-randomised stud-
ies in severe PPH. The risk of thromboembolic complica-
tions has not been systematically investigated. To be effec-
tive, rhVIIa requires correction of hypothermia, acidosis, 
fibrinogen levels, and anaemia [100]. If haemorrhage could 
not be controlled by other measures, rhFVIIa could lower 
the need of second-line therapies [101]. In a prospective 
cohort study with 22 patients with severe PPH rhVIIa con-
tributed to the control of PPH and hysterectomy was avoided 
[102]. In life-threatening PPH, rFVIIa administration might 
be used. However, this should not replace or postpone vital 
interventions. It is of note that patients should be monitored 
to detect thromboembolism, especially if rhVIIa is given in 
the combination with tranexamic acid.
Surgical/interventional strategies as second‑line 
treatments for PPH
Uterine balloon tamponade
It is possible to manage the majority of severe PPH situ-
ations when blood loss is rapidly minimised and stopped 
using appropriate methods, for example, with uterotonics 
and other interventions. However, these therapies are not 
always effective in stopping severe bleeding. Therefore, to 
manage severe PPH and reduce morbidity and mortality, it is 
necessary to combine several methods including second-line 
treatments which can be applied even in low-resource struc-
tures. In this case, uterine balloon tamponade can be useful. 
It is a relatively simple and effective approach. A balloon 
device (Bakri-balloon) is introduced in the uterus and filled 
with fluid to apply pressure on the uterine walls and allow 
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haemorrhage discontinuation. When this method works to 
stop bleeding, it is unlikely that the patient needs surgery (in 
particular, laparotomy after vaginal birth) and RBC trans-
fusions. In the situation, where balloon tamponade is not 
fully effective to stop severe bleeding, it can help to stabi-
lise the situation until the patient is transferred to a struc-
ture which has more treatment options (bridging method). 
Balloon tamponade works quite fast (5–10 min.) after start 
of use. Balloon tamponade can help in unmanageable PPH 
or in areas/structures, where efficient methods for PPH are 
unavailable. Therefore, it has been recommended in several 
guidelines (The WHO, the American College of Obstetri-
cians and Gynaecologists, the International Federation of 
Gynaecology and Obstetrics, the RCOG, and the Interna-
tional Confederation of Midwives) [103–105].
Embolization
Arterial embolization after PPH can be successful in arrest-
ing the bleeding [106]. Prerequisites for embolization are 
availability and logistics of interventional radiology, and 
haemodynamic stability of the patient. In situations, where 
an interventional radiologist or the logistics to perform 
arterial occlusion or embolization are not available, uterine 
balloon tamponade should be considered as first-line treat-
ment. Balloon tamponade can also can be used to bridge the 
time until embolization. Longitudinal trials in patients who 
underwent arterial embolization to manage PPH showed 
that this method does not affect the following menstruation 
cycles or fertility [53]. If artery ligation failed, selective 
arterial occlusion might be considered [107]. Embolization 
seems to work to manage severe postpartum blood loss and 
to conserve fertility especially in life-threatening situations.
Uterine compression sutures
When the relatively non-invasive treatment of Balloon tam-
ponade does not stop PPH, the next step is the use of more 
invasive treatments requiring laparotomy. If no active bleed-
ing vessel is identified, uterine compression sutures can be 
applied. In 1997, the B-Lynch uterine compression suture 
was introduced and became the most widely performed 
suture. Subsequently, several other uterine compression 
sutures were described, such as Hayman, Cho, Pereira, 
Ouahba, or Hackethal suture. Up to date, randomised tri-
als comparing the compression sutures to other procedures 
are missing. The average rate of haemostasis is 97% with a 
range from 76% to 100% [108]. The success rate is higher if 
compression suture is performed within 1 h after delivery. 
The risk for hysterectomy is increased by fourfolds if there is 
a 2–6 h delay (after delivery) of uterine compression suture 
[109].
Ligature of the uterine and utero-ovarian arteries is fur-
ther surgical interventions and can decrease uterine bleeding 
by reducing perfusion pressure in the myometrium. It does 
not harm the uterus and does not appear to impact reproduc-
tive function [110]. Iliac artery ligation remains challenging 
even for an experienced pelvic surgeon [111]. Therefore, 
arterial embolization, uterine artery ligation, and uterine 
compression sutures largely replaced this procedure.
Cell salvage
Cell salvage is the process of washing and returning intra-
operatively collected RBC to the patient. Cell salvage is 
frequently used in non-obstetric surgeries with anticipated 
major blood loss. In obstetrics, cell salvage is recommended 
in individual situations with anticipated high blood loss, 
such as placenta accreta spectrum disorder, while it is not 
recommended as a routine procedure for caesarean delivery 
[112]. Cell salvage is frequently acceptable to Jehova’s wit-
nesses, although individual consent has to be sought.
Postpartum hysterectomy
If all treatments mentioned above fail, hysterectomy (HE) 
is the last resort of PPH treatment. As such, it is also asso-
ciated with further blood loss. Therefore, the decision for 
HE should not be delayed too much and decision taken too 
late when there is haemodynamic instability, severe coagu-
lation deficiency, and further signs of decompensation such 
as tissue hypoxia or hyperthermia. On the other hand, hys-
terectomy leads to definitive loss of fertility, reason why it 
should be used only as last resort treatment. An experienced 
clinician should decide if and when HE is necessary. The 
request of a second opinion is advised when possible [113]. 
Postpartum HE requires an experienced gynaecologic sur-
geon. It is usually performed as supracervical HE to shorten 
operation time and decrease additional blood-loss. Only in 
placenta previa and/or morbidly adherent placenta, it is often 
necessary to perform a total HE including the cervix.
Active and non‑active bleeding in delivery 
and postpartum haemorrhage
In general, blood transfusions hold risks. Furthermore, for 
religious reasons, some women such Jehovah’s witnesses—
decline RBC. For these reasons, there must be a clear indica-
tion for RBC transfusion, such as risk of ongoing haemor-
rhage with severe anaemia or cardiac decompensation [114]. 
A recent paper [114] identified only one small randomised 
controlled trial with 72 pregnant women investigating the 
role of proactive (prophylactic) or reactive (restrictive), 
administration of blood. The conclusion of the authors was 
not in favour of prophylactic blood transfusion [115]. There 
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are missing studies of the consequences of blood transfusion 
on the mortality of the mothers or the new-borns. Thus, any 
endorsement from experts is based on the clinical experi-
ence but not evidence based [39]. Severe anaemia during 
pregnancy was linked to low foetal oxygenation, resulting 
in foetal morbidity and mortality, and reduction of amni-
otic fluid volume [116, 117]. In these situations, foetal 
surveillance and blood transfusion in the mother need to 
be taken into consideration. [35, 43]. In the case of severe 
anaemia in pregnancy (e.g., Hb < 7 g/dL), the patient should 
be addressed to a specialized foeto-maternal medicine care 
centre. If there is no active bleeding but transfusion deems to 
be necessary, the minimum amount of blood should be trans-
fused (single-unit). Subsequently, clinical and laboratory 
evaluation should be performed to reassess the additional 
need of blood transfusion. Iron stores cannot be replenished 
by a single RBC concentrate (~ 240 mg iron); thus, the addi-
tional administration of parenteral iron is recommended. 
Importantly, restrictive recommendations for transfusion 
apply only for patients with stable circulation and no active 
bleeding. In women with active bleeding, transfusions may 
not be avoidable in many patients and can safe life. Nev-
ertheless, some women—also if necessary—do not accept 
blood products, for example Jehovah`s witnesses. In those 
women, PBM improves both short- and long-term outcomes, 
due to the synergies between preoperative haematological 
values optimisation, good volume management, and precise 
methods of surgery [118], but when these steps fail with 
active bleeding, the obstetrician has to choose expedite tech-
nique to fix the situation i.g. hysterectomy.
Management of women postpartum
Evaluation of postpartum haemoglobin
To determine postpartum haemoglobin might have a great 
impact on the mother’s well-being. Researchers from Spain 
found an association between ferritin concentration during 
the immediate postpartum period and postpartum depression 
[119]. In women with postpartum depression (PPD), the fer-
ritin concentration was lower and more women had depleted 
iron stores than those without depression. On average, more 
patients in the PPD arm compared to the non-PPD arm had 
depleted iron stores without marginal iron deficiency. The 
problem with these studies is that ferritin levels postpartum 
are often erroneously high due to an inflammation in particu-
lar after caesarean section and PPH, as ferritin is increased 
in the acute phase of inflammation. We, therefore, suggest 
omitting ferritin-level measurements in the postpartum 
period and instead measure Hb, ideally around 48 h after 
birth as this usually represents the Hb nadir. Nevertheless, 
there are increased iron needs during pregnancy and postpar-
tum both directly through to the demands of the developing 
foetus, and indirectly through breastfeeding depletes iron 
stores. Iron deficiency in postpartum women may alter neu-
rotransmitter and myelin metabolism and thus increase the 
risk of PPD in susceptible women. Recently, a Danish study 
showed a correlation between iron deficiency anaemia and 
high score on the EPDS (Edinburgh Postpartum Depression 
Scale). Half of women involved in PPD are undiagnosed 
and untreated. Appropriate iron treatment may, therefore, 
decrease the incidence of PPD in postpartum iron deficiency.
Postpartum anaemia
Iron deficiency anaemia is very frequent in postpartum 
and is usually due to postpartum blood loss. It is consid-
ered as an important health concern. The SSGO defines 
postpartum anaemia as an Hb < 12 g/dL within ~ 48 h after 
delivery (the nadir) [40]. Others define postpartum anae-
mia as an Hb <11 g/dL 1 week postpartum or Hb <12 g/
dL 8 week postpartum [32, 120, 121]. Many women suffer 
from postpartum anaemia. From 43.807 German women 
who delivered in 1993–2008, 22% had postpartum anae-
mia with an Hb <10 g/dL after 24–48 h from birth [122]. 
In Denmark, 14% of women who received iron suffered 
from postpartum anaemia 1 week after vaginal birth in 
comparison with a prevalence of 24% in those who did not 
receive iron [123]. According to the SSGO, at least one-
third up to half of postpartum woman in Switzerland are 
anaemic [40]. Often, postpartum anaemia is due to prepar-
tum iron-deficiency with or without anaemia and/or acute 
blood loss during delivery [122, 124, 125]. There are sev-
eral factors, which could increase the risk of PPH [i.g. eth-
nicity, inflammation (post-caesarean section), vitamin B12 
or folic acid deficiency, multiparity, haemoglobinopathies, 
and infections] [122, 126–128]. Both postpartum anaemia 
and iron deficiency can induce several consequences such 
as reduction of physical and cognitive capacity (fatigue, 
dyspnoea, etc.), higher susceptibility to infections, disabil-
ity of breast feeding, higher risk of postpartum depression 
[122], and compromised ability of bonding to the baby 
[129]. Postpartum anaemia may also increase health-care 
costs [114]. Thus, the reasons that could lead to postpar-
tum anaemia should be foreseen and corrected in the best 
way. The postpartum Hb concentration should be allowed 
to stabilise after delivery for at least 48 h before a reli-
able diagnosis of postpartum anaemia is performed. To 
have a reliable Hb value, one should wait 1 week after 
delivery [121]. However, if anaemia or iron deficiency is 
misdiagnosed in immediate postpartum, an estimation of 
serum ferritin together with a complete blood count (CBC) 
4–8 week postpartum is a good alternative [128]. To have 
an unaltered serum ferritin level, inflammation should be 
excluded by measuring the CRP [38].
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Prevention and treatment of postpartum anaemia
Prepartum iron deficiency with or without anaemia is closely 
related to anaemia after birth. As postpartum anaemia can 
be severe and have durable negative consequences of the 
mother and her child, postpartum anaemia should be avoided 
by filling up iron stores during (or even before) pregnancy 
[130]. According to available studies, oral iron supplementa-
tion during pregnancy can lower the risk of anaemia during 
pregnancy and postpartum [131–133]. In case of asympto-
matic mild anaemia, the woman should be treated with oral 
iron (80–200 mg/day for a minimal duration of 3 months) 
[40, 130]. The patient should be informed on the correct 
way of oral iron intake to avoid food interactions and have 
an optimal absorption [41].
Currently available information suggests that intravenous 
iron in the postpartum period is beneficial and more effi-
cient than oral iron, particularly in women with moderate 
or severe anaemia [134, 135]. In the systematic review by 
Sultan et al., Hb at 6 week postpartum were almost 10 g/dL 
higher in women with postpartum anaemia who received 
intravenous iron compared to oral iron. Given the reassuring 
safety profile of intravenous iron, the weaker Hb response 
and higher risk of gastrointestinal side-effects with oral iron 
use, i.v. iron can be considered as a viable treatment option 
for postpartum iron deficiency anaemia [135].
After birth, treatment of iron deficiency anaemia includes 
the recommendations according to the SSGO [40]:
– Hb from 9.5 g/dL to 12 g/dL: Oral iron therapy. If oral 
iron medication is badly tolerated due to gastrointestinal 
side effects, intravenous iron treatment should be admin-
istered.
– Hb < 9.5 g/dL: intravenous iron therapy (as first line 
therapy, ferric carboxymaltose as first-choice product).
Basis of this recommendation are randomised studies 
showing a more rapid increase of haemoglobin after intra-
venous iron as compared to oral iron [45, 46]. In particular, 
in the postpartum period, a rapid recovery is essential for 
successful breastfeeding and that the mother is able to cope 
with all the challenges of care for the neonate.
In case of caesarean section or postpartal inflammation, 
oral iron may not be efficiently absorbed because of the 
increased Hepcidin level (iron regulator) [136]. Therefore, 
in such situations (women with inflammation, severe anae-
mia or refusing RBC transfusion like Jehovah’s witnesses) 
parenteral iron should be considered as first-line treatment.
The decision to administer RBC transfusion should be 
considered according to postpartum Hb value as well as 
clinical symptoms. It can be appropriate when Hb value 
is <6 g/dL, or between 7 and 9 g/dL if symptoms of anae-
mia are severe. As a principle, in postpartum women without 
active bleeding, transfusion should be restrictive and include 
administration of only one packed red blood cell, followed 
by Hb measurement and clinical evaluation to decide if more 
is necessary. When Hb value is > 9 g/dL, blood transfusion 
is barely needed [35, 40, 43].
Conclusion
All pregnant women have a significant risk for PPH. Risk 
factors do exist; however, 60% of women with PPH do not 
have a risk factor. Patient blood management in obstetrics 
must, therefore, not only be focused on women with identi-
fied risk factor of PPH, but on all pregnant women [30].
PBM in obstetrics is based on 3 main pillars:
1. Measures during pregnancy.
  Identification of anaemia and its cause, treatment of 
anaemia, early treatment of iron deficiency, optimization 
of red blood cell mass in view of delivery.
  Identify patients with a very high risk for PPH (for 
example placenta praevia, placenta increta, large uter-
ine fibroma, etc.), to appropriately plan logistics, man-
agement of delivery and PBM. They should preferably 
deliver in a tertiary care centre.
2. Measures during delivery.
  Use pre-emptive administration of uterotonics after 
delivery to prevent PPH.
  Minimize blood loss during delivery using appropri-
ate surgical technique in caesarean section.
  In case of PPH, use appropriate modern measures 
to minimize blood loss, including balloon tamponade, 
tranexamic acid and fibrinogen administration, recom-
binant activated factor VII administration, uterine com-
pression sutures, uterine artery embolization, and cell 
salvage.
3. Measures during the postpartum phase.
  Manage postpartum anaemia by appropriate iron 
administration. Optimise the patient’s physiological 
response to anaemia, treat infections and maximize oxy-
gen delivery to minimize transfusions. Use differential 
management in active bleeding and non-active bleeding 
phase of PPH: During active and heavy bleeding, blood 
transfusions are often necessary, sometimes massive 
transfusions, to save the life of the patient. However, 
during non-active bleeding phase unnecessary red blood 
cell transfusions must be avoided, and a restrictive use 
of blood transfusion should be applied. In that case, i.v. 
iron infusion seems a better option than oral supplemen-
tation to resolve postpartum anaemia.
These three main pillars should be kept in mind by all 
professionals taking care of pregnant women, including 
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obstetricians, general practitioners, midwifes, and anaes-
thesiologists. PBM should be more thoroughly introduced 
in clinical guidance for pregnancy care and PPH of national 
and international obstetrical societies.
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